Artery is presenting Phase 1 Single Ascending Dose data from the successful and recently completed Clinical Trial ATI-CS-001 at CTAD24 conference in Madrid, Spain.

Artery is presenting Phase 1 Single Ascending Dose data from the successful and recently completed Clinical Trial ATI-CS-001 at CTAD24 conference in Madrid, Spain. ​​ Title: A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses of CS6253 in Healthy Volunteers. Location: Poster Session 1. Date: October 29 - 30, 2024. Poster #: P032. ​​

The release as fetched from its publisher. arterytx.com ↗